Targeted Oncology reviews trending news online for the week of October 30, 2020, including recent news from the FDA, updates in oncology, and new information regarding COVID-19.
This week, the FDA granted approval to the FoundationOne Liquid biopsy assay as a companion diagnostic for several indications.
The FDA also granted an Orphan Drug designation for soft tissue sarcoma, a Priority Review designation for PD-L1-high advanced or metastatic non–small cell lung cancer (NSCLC), as well as a Priority Review for HER2-positive metastatic gastric/gastroesophageal junction adenocarcinoma.
In an interview with Targeted Oncology, Masahiro Tsuboi, MD, discussed the findings from the ADAURA study, which explored the role of osimertinib (Tagrisso) as treatment of patients with early-stage EGFR-mutant NSCLC following a complete tumor resection.
The IDH1 inhibitor olutasidenib showed a favorable safety profile in patients with relapsed/refractory acute myeloid leukemia treated in a phase 1/2 clinical trial.
In an interview with Targeted Oncology, Naomi Haas, MD, discussed the role of PSMA in the treatment landscape of prostate cancer and highlighted the key findings from the phase 1 chimeric antigen receptor T-cell trial in metastatic castration resistance prostate cancer.
Adagrasib (MRTX849) demonstrated promising antitumor activity as monotherapy in patients with previously treated KRAS G12C–mutant NSCLC.
The treatment landscape of mantle cell lymphoma has been enriched with the development of several targeted therapies, but patients considered to have high-risk disease tend to have a worse prognosis, despite the latest development in the field.
Bradley McGregor, MD, discusses the current treatment landscape for patients with advanced or metastatic renal cell carcinoma, which has significantly evolved over the last few years.
Jennifer R. Brown, MD, PhD, and Alan Skarbnik, MD, describe the rationale for treating chronic lymphocytic leukemia with BTK inhibition, and explore current trends in data that impact treatment selection.
Due to efforts to reduce exposure to the coronavirus, oncology patient volumes initially decreased, treatment regimens were disrupted or altered, and new cancer diagnoses also slowed. This affected not only patient care, but also clinical trials.